<table>
<thead>
<tr>
<th>Title</th>
<th>Apaf-1- and Caspase-8-independent apoptosis.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Imao, T; Nagata, S</td>
</tr>
<tr>
<td>Citation</td>
<td>Cell death and differentiation (2013), 20(2): 343-352</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2013-02</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/2433/178680">http://hdl.handle.net/2433/178680</a></td>
</tr>
<tr>
<td>Rights</td>
<td>© 2013 ADMC Associazione Differenziamento Cellulare; この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.</td>
</tr>
<tr>
<td>Type</td>
<td>Journal Article</td>
</tr>
<tr>
<td>Textversion</td>
<td>author</td>
</tr>
</tbody>
</table>

Kyoto University
Apaf-1- and Caspase-8-independent apoptosis

Running title: Apaf-1- and Caspase-8-independent apoptosis

Takeshi Imao¹ and Shigekazu Nagata¹,²

¹Department of Medical Chemistry, Graduate School of Medicine, Kyoto University, Yoshida, Sakyo-ku, Kyoto 606-8501, Japan
²Core Research for Evolutional Science and Technology, Japan Science and Technology Corporation, Kyoto 606-8501, Japan

Correspondence should be addressed to:
Shigekazu Nagata,
Department of Medical Chemistry, Graduate School of Medicine, Kyoto University, Yoshida-Konoe, Sakyo, Kyoto 606-8501, Japan
Tel: 81-75-753-9441, Fax: 81-75-753-9446,
E-mail: snagata@mfour.med.kyoto-u.ac.jp
Abstract

Two major apoptosis pathways, the mitochondrial and death receptor pathways, are well recognized. Here we established cell lines from the fetal thymus of Apaf-1-, Caspase-9-, or Bax/Bak-deficient mice. These cell lines were resistant to apoptosis induced by DNA-damaging agents, RNA or protein-synthesis inhibitors, or stress in the endoplasmic reticulum. However, they underwent efficient apoptosis when treated with kinase inhibitors such as staurosporine and H-89, indicating that these inhibitors induce a caspase-dependent apoptosis that is different from the mitochondrial pathway. CrmA, a Caspase-8 inhibitor, did not prevent the staurosporine-induced apoptosis of fetal thymic cell lines, suggesting that the death receptor pathway was also not involved in this process. The staurosporine-induced cell death was inhibited by okadaic acid, a serine-threonine phosphatase inhibitor, suggesting that de-phosphorylation of a pro-apoptotic molecule triggered the death process, or that phosphorylation of an anti-apoptotic molecule could block the process. Cells of various types (fetal thymocytes, bone marrows, thymocytes, and splenocytes) but not embryonic fibroblasts were sensitive to the non-canonical staurosporine-induced apoptosis, suggesting that the non-canonical apoptosis pathway is tissue-specific.
**Key Words:** apoptosis, kinase inhibitors, caspase, non-canonical apoptosis, tissue-specificity

**Abbreviations:** E, embryonic day; FADD, Fas-associated protein with death domain; FasL, Fas ligand; IFET, immortalized fetal thymocyte; MEF, mouse embryonic fibroblast; PARP, poly(ADP)ribose polymerase; TRAIL, TNF-related apoptosis-inducing ligand.
**Introduction**

Apoptosis serves to eliminate cells that are useless (e.g., interdigital cells, non-reactive lymphocytes) or harmful (e.g., tumor cells and auto-reactive lymphocytes).

Deregulated apoptosis causes a variety of diseases. That is, a defect in apoptosis can lead to the development of tumors and autoimmune diseases, whereas an excess of apoptosis can cause organ failure (1). Two apoptotic signaling pathways have been well characterized in mammals, the death receptor and mitochondrial pathways (also known as the extrinsic and intrinsic pathways, respectively)(2-4). In the death receptor pathway, the binding of a death factor such as Fas ligand (FasL), TNF, or TNF-related apoptosis-inducing ligand (TRAIL) to its receptor triggers a signaling cascade that leads to the activation, via an adaptor, Fas-Associated protein with Death Domain (FADD), of a caspase cascade consisting of Caspase-8 and Caspase-3. In the mitochondrial pathway, cytotoxic insults up-regulate or activate BH3-only proteins that activate and oligomerize Bax and Bak, and the oligomerized Bcl-2 family members Bax/Bak cause the release of cytochrome c from mitochondria into the cytosol (5). Cytochrome c then forms a complex with Apaf-1, and the cytochrome c/Apaf-1 complex, called the apoptosome, activates Caspase-9, which in turn activates Caspase-3 (6, 7).

The role of FADD and Caspase-8 in the death receptor-induced apoptosis pathway was confirmed by the establishment of their knock-out mice (8, 9). On the other hand, conflicting reports have been published on the roles of the signaling molecules in the mitochondrial pathway. Establishing knock-out mice, Cecconi et al. (10), Yoshida et al.
and Kuida et al. (12) originally reported that Apaf-1 and caspase-9 are indispensable for genotoxic agent-induced apoptosis. However, this idea was later challenged by Marsden et al. (13), who showed that hemopoietic cells that lack Apaf-1 or Caspase-9 can undergo Bcl-2-regulated Caspase-dependent apoptosis. We recently reported that staurosporine, but not etoposide, activates Caspase-3 in embryonic day (E)14.5 fetal thymocytes, in an Apaf-1-independent manner (14). Moreover, activated Caspase-3 can be detected in situ in the E14.5 Apaf-1/- fetal thymus, suggesting that an Apaf-1-independent intrinsic apoptotic pathway exists in these cells.

Here, to characterize this Apaf-1-independent pathway, we established cell lines (immortalized fetal thymocytes, IFETs) from the fetal thymus of wild-type and mutant mice. The Apaf-1/- IFETs were resistant to genotoxic agent-induced apoptosis, but staurosporine caused efficient caspase-dependent apoptosis. Neither a null mutation of Caspase-9 nor the double-mutation of Bax/Bak abolished the staurosporine-induced apoptosis of IFETs. The expression of CrmA, a Caspase-8 inhibitor (15), did not inhibit the staurosporine-induced apoptosis, either, indicating that the death receptor pathway was not used in this death process. This non-canonical Apaf-1- and Caspase-8-independent apoptosis-signaling pathway triggered by staurosporine was observed in lymphoid and myeloid tissues such as fetal thymocytes and bone marrow cells, but was barely detectable in embryonic fibroblasts. Together, these results suggest the existence of a new tissue-specific apoptotic pathway that is distinct from the death receptor and mitochondrial pathways.
Results

Establishment of *Apaf-1*-null fetal thymocyte cell line. We previously observed that Caspase-3 is activated in the *Apaf-1*-null fetal thymus (14). To characterize the Apaf-1-independent apoptosis biochemically, it was essential to establish *Apaf-1*-null cell lines. Mouse fetal thymocytes were immortalized by infecting them with mouse retrovirus carrying c-myc and H-ras\textsuperscript{v12}, using the RetroNectin-bound virus method. Several hundreds transformants were obtained from the pair of thymic lobes of an *Apaf-1\textsuperscript{+/+}* or *Apaf-1\textsuperscript{−/−}* E14.5 embryo. The transformants were cloned by limiting dilution, and termed IFETs (immortalized fetal thymocytes). The targeted disruption of the *Apaf-1* gene, or deletion of its exon 5, in *Apaf-1\textsuperscript{+/−}* IFETs was confirmed by PCR analysis of the genomic DNA (Supplementary Figure S1A).

Incubating cell lysates with cytochrome *c* and dATP activates Caspase-3 in an Apaf-1-dependent manner (16). Accordingly, when extracts of *Apaf-1\textsuperscript{+/+}* but not *Apaf-1\textsuperscript{−/−}* IFET were incubated with cytochrome *c* and dATP, the Caspase-3 activation was observed (Supplementary Figure S1B), confirming that Apaf-1 was functionally inactivated by the deletion of its exon 5. The *Apaf-1\textsuperscript{+/+}* and *Apaf-1\textsuperscript{−/−}* IFETs grew equally well, with no requirement for specific growth factors. The surface phenotype of both the *Apaf-1\textsuperscript{+/+}* and *Apaf-1\textsuperscript{−/−}* IFETs was Thy1.2\textsuperscript{+}CD25\textsuperscript{−}CD44\textsuperscript{+} (Supplementary Figure S2), although the Thy1.2 was gradually down-regulated after repeated passages. These results suggested that the IFETs established here were T-cell lineage cells at the early stage of development.
Apaf-1-independent caspase-dependent cell death induced by staurosporine. Next, the wild-type and \textit{Apaf-1}^{-/\textit{+}} IFETs were treated with staurosporine or etoposide. As shown in Figure 1A, the \textit{Apaf-1}-null mutation blocked the etoposide-induced cell death. However, it had no effect on the staurosporine-induced cell death, and more than 90% of the staurosporine-treated \textit{Apaf-1}^{-/\textit{+}} IFETs died within 12 h. A low concentration (50 μM) of caspase inhibitor (Q-VD-OPh) (17) efficiently blocked the staurosporine-induced death of \textit{Apaf-1}^{-/\textit{+}} as well as the wild-type IFETs (Figure 1B), although Q-VD-OPh failed to rescue the staurosporine-induced cell-cycle arrest (Supplementary Figure S3). Not only procaspase-3 but also other caspases such as procaspase-2, -7, -8 and -9 were efficiently processed into its active form upon staurosporine treatment without Apaf-1 (Figure 1C), in sharp contrast to the lack of processing of procaspases by etoposide without Apaf-1. The concentration of staurosporine required to activate Caspase-3 in \textit{Apaf-1}^{-/\textit{+}} IFETs seems to be higher than that required for the wild-type IFETs, but 0.1 μM staurosporine could still activate Caspase-3 in \textit{Apaf-1}^{-/\textit{+}} IFETs in a time-dependent manner (Supplementary Figure S4).

During apoptotic cell death, poly(ADP)ribose polymerase (PARP) is cleaved, and phosphatidylserine is exposed to the cell surface (18, 19). Staurosporine, but not etoposide, caused PARP processing (Figure 1C) and phosphatidylserine-exposure without Apaf-1 (Figure 1D), confirming that executor caspases were activated by staurosporine through an Apaf-1-independent mechanism.

**No requirement for Caspase-9, Bax/Bak or Caspase-8 in staurosporine-induced**
cell death. Caspase-8 and -9 are essential for executing the extrinsic and intrinsic pathways of apoptosis, respectively (8, 12). To examine the requirement for Caspase-9 in the staurosporine-induced activation of Caspase-3, IFETs were established from Caspase-9-/- fetal thymocytes (Supplementary Figure S1C). As expected, etoposide could not activate Caspase-3 in the absence of Caspase-9, but staurosporine readily activated Caspase-3 without Caspase-9 (Figure 2A). Accordingly, over-expression of caspase 9 in Caspase 9-/-IFETs had no effect on the staurosporine induced Caspase-3 activation (data not shown). IFETs were then established from the fetal thymocytes of Bax-/-Bak-/- embryos (20)(Supplementary Figure S1D). Staurosporine but not etoposide activated Caspase-3 in the Bax-/-Bak-/- IFETs (Figure 2A). The release of cytochrome c is one of the major characteristics of the mitochondrial pathway of apoptosis (21). When the wild-type and Apaf-1-/- IFETs were treated with staurosporine, the release of cytochrome c was observed, but there was no release of cytochrome c in Bax/Bak-/- IFETs (Figure 2B), indicating that cytochrome c was not involved in the new apoptosis pathway. Accordingly, transformation of Apaf-1-/- IFETs with human Bcl-2 had no effect on the staurosporine-induced Caspase-3 activation in Apaf-1-/- IFETs (Supplementary Figure S5). These results confirmed that staurosporine could activate Caspase-3 in IFETs without the mitochondrial apoptotic pathway.

To examine the involvement of the extrinsic pathway of apoptosis in the staurosporine-induced caspase activation, Caspase-9-/- IFETs were stably transformed with CrmA, a cowpox virus protein that inhibits Caspase-1 and -8 (15). At their early developmental stage, T cells do not express Fas (22, 23). Thus, as expected, Fas was
not expressed in the *Caspase-9*-/ IFETs, and the IFETs were resistant to FasL-induced apoptosis (data not shown). When the *Caspase-9*-/ IFETs were transformed with Fas (Supplementary Figure S6), the FasL treatment efficiently activated Caspase-3, and this activation was inhibited by CrmA (Figure 2C). On the other hand, staurosporine activated Caspase-3 even in the presence of CrmA in *Caspase-9*-/ IFETs (Figure 2C). These results indicated that staurosporine causes a caspase-dependent cell death that does not use the mitochondrial or the death receptor pathway.

Various reagents activate Caspase-3 to induce apoptotic cell death. As shown in Figure 3, treatment of wild-type IFETs with 2.5 μg/ml tunicamycin, 3 μg/ml actinomycin D, 10 μg/ml cycloheximide, or γ-ray (5 Gy) irradiation efficiently activated Caspase-3, and the cells were dead within 48 h in most cases (data not shown). In contrast, IFETs lacking *Apaf-1, Caspase-9, or Bax/Bak* were completely resistant to the apoptosis induced by these reagents (Figure 3A-C, and 3E). Similarly, Caspase-3 was not activated when *Bax*/*Bak*-/ IFETs were treated with γ-rays (Figure 3D). These results indicated that most apoptosis-inducing reagents, such as DNA-damaging agents and protein-synthesis and RNA-synthesis inhibitors, required the mitochondrial pathway to activate Caspase-3.

**Effect of phosphatase inhibitors on the staurosporine-induced cell death.**

Staurosporine is a multi-kinase inhibitor, but it also inhibits other enzymes such as ABC transporters and topoisomerase (24, 25). Thus, it is unclear whether the inhibition of a kinase or other targets led to the induction of the Apaf-1-independent apoptosis. To
address this question, we investigated whether phosphatase inhibitors suppressed the staurosporine-induced apoptosis in Apaf-1\(^{-/-}\) IFETs. As shown in Figure 4, okadaic acid, which is a serine/threonine phosphatase inhibitor, suppressed the staurosporine-induced Caspase-3 activation (Figure 4A) and cell death in Apaf-1\(^{-/-}\) IFETs (Figure 4B). On the other hand, sodium orthovanadate, a tyrosine phosphatase inhibitor, had only a small effect on the staurosporine-induced Caspase-3 activation and cell death in Apaf-1\(^{-/-}\) IFETs (Figure 4A and data not shown). These results suggest that staurosporine induces Apaf-1-independent apoptosis by inhibiting a serine/threonine kinase(s); however, we cannot formally rule out the possibility that the phosphatase inhibitors simply enhanced an anti-apoptotic pathway.

To confirm that the inhibition of kinases induced apoptotic cell death, we examined the effect of various kinase inhibitors on the apoptotic cell death. We used staurosporine analogues that had different specificities for target kinases (24, 25), H-7 and its derivatives (26), and inhibitors of MAPK and PI3K signaling pathways. Among the ten staurosporine analogues tested, four (UCN-01, GF109203X, Ro31-8220, and K252a) activated Caspase-3 in Apaf-1\(^{-/-}\) IFETs at 2.5-50 \(\mu\)M, while the others had no effect at least, at the same concentration (Figure 4C). The treatment of Apaf-1\(^{-/-}\) IFETs with 1.0 mM H-7, H-8 or H-9 did not kill them, but H-8’s H-89 derivative efficiently killed the Apaf-1\(^{-/-}\) IFETs and activated Caspase-3 at 50 \(\mu\)M. On the other hand, none of the MAPK-PI3K inhibitors tested (U0126, SP600125, SB239063, and LY294002) activated Caspase-3 in the Apaf-1\(^{-/-}\) IFETs (Supplementary Figure S7).
Cell-specific mitochondria death pathway-independent Caspase-3 activation by staurosporine. To examine whether the new apoptosis pathway that was independent from the death receptor and mitochondrial pathways was present in other cell types, Apaf-1-null embryonic fibroblasts were prepared. As shown in Figure 5A, treatment of the primary wild-type MEFs with 10 μM staurosporine generated active Caspase-3, while no active Caspase-3 was observed with Apaf-1⁻/⁻ MEFs, indicating that MEFs carry only the canonical apoptotic pathway.

To examine whether the non-canonical pathway was present in adult hemopoietic and lymphoid cells, Tie2Cre⁺Baxββ−Bak⁺/⁻ mice {Schlaeger, 2005 #5700} {Kisanuki, 2001 #5322;Takeuchi, 2005 #5305}, in which the floxed allele of the Bax gene was deleted in hemopoietic and endothelial cells by Cre-mediated recombination (Supplementary Figure S8A) were analyzed. Western blotting analysis showed that adult thymocytes, bone marrow cells and splenocytes from Baxββ−Bak⁺/⁻ mice at the age of 7-9 weeks contained the 21-kDa Bax. In contrast, the thymocytes, bone marrow cells, and splenocytes from the Tie2Cre⁺Baxββ−Bak⁺/⁻ mice did not show this band (Figure 5C, 5D and 5E), indicating that the Bax gene was fully deleted in these cells. As expected from the null-mutation of Bak, the thymocytes, bone marrow cells, and splenocytes from the Baxββ−Bak⁺/⁻ mice did not carry 28 kDa Bak (Supplementary Figure S8B). Thymocytes from Baxββ−Bak⁺/⁻ mice spontaneously die, and this death process was accelerated by treating with staurosporine (Figure 5B). The lack of Bax/Bak in Tie2Cre⁺Baxββ−Bak⁺/⁻ strongly inhibited the spontaneous death, yet staurosporine killed the Tie2Cre⁺Baxββ−Bak⁺/⁻ thymocytes.
When the thymocytes, bone marrow cells, and splenocytes from the $Bax^{fl/fl}Bak^{-/-}$ mice were treated with staurosporine or etoposide, both reagents produced the active form of Caspase-3 (Figure 5C, 5D and 5E), as in wild-type fetal thymocytes. Deleting $Bax$ and $Bak$ in the $\text{Tie2Cre}^+Bax^{fl/fl}Bak^{-/-}$ mice completely abolished the ability of etoposide to activate Caspase-3 in these cells. On the other hand, staurosporine could still activate the Caspase-3 in the absence of $Bax$ and $Bak$. These results indicated that the non-canonical apoptosis pathway is present in lymphoid and myeloid cells such as thymocytes, splenocytes and bone marrow cells, but not in fibroblasts.
Discussion

Caspase-dependent apoptotic cell death has been thought to be mediated by two pathways: the intrinsic mitochondrial pathway and the extrinsic death receptor pathway (27). Here we showed that staurosporine, a non-selective inhibitor of diverse kinases (24), could activate Caspase-3 to kill cells, *via* two different pathways. One pathway required *Apaf-1*, while the other did not. The *Apaf-1*-independent caspase activation did not require *Bax/Bak or Caspase-9*, and was not inhibited by Bcl-2, and occurred without the release of cytochrome *c* from mitochondria, suggesting that the mitochondrial pathway was involved in this death process. CrmA, an inhibitor of Caspase-8 (15), also had little effect on the *Apaf-1*-independent caspase activation, suggesting that the death receptor pathway was also not involved in this process.

Recently, the activation of inflammasomes by pathogens was shown to cause the Caspase-1-dependent cell death of macrophages and dendritic cells, which is called pyroptosis (28, 29). CrmA inhibits not only Caspase-8 but also Caspase-1 (15), suggesting that the staurosporine-induced apoptotic pathway identified here was not pyroptosis.

The *Apaf-1*- and *Caspase-1/8*-independent non-canonical apoptotic pathway was activated by various kinase inhibitors, such as staurosporine, UCN-01, a staurosporine-derivative, and H-89. The activation of Caspase-3 by these kinase inhibitors was inhibited by okadaic acid, a phosphatase inhibitor. A simple idea is that growing cells carry a phosphatase(s) that leads to the activation of Caspase-3, and specific kinases prevent the phosphatase-induced Caspase-3 activation by keeping its
target phosphorylated. Phosphatase inhibitors were previously shown to inhibit the mitochondrial and death receptor pathways (30), in which phosphatases seem to increase the death-signaling that requires de-phosphorylation. Therefore, it is possible that cells carry a pro-apoptotic molecule(s) that has the potential to induce caspase-dependent apoptosis if it is not phosphorylated. Thus, a kinase(s) in growing cells may prevent the de-phosphorylation of this molecule, and kinase inhibitors block this process to generate the active pro-apoptotic molecule(s). Phosphatase inhibitors could prevent the de-phosphorylation of the pro-apoptotic molecule, or enhance an anti-apoptotic pathway such as the NF-κB pathway, by keeping the signaling molecules phosphorylated. Staurosporine, H-8, and their derivatives have different target specificities (24, 26, 31). A more detailed analysis of the death-inducing ability of various kinase inhibitors may help elucidate the non-canonical death-signaling pathway.

Staurosporine was originally found as a molecule that induces a Bcl-2-inhibitable apoptotic death, suggesting it causes cell death via the mitochondrial pathway (32, 33). In fact, Yoshida et al. (11) by preparing Apaf-1-deficient mice, showed that staurosporine can not activate caspase in the absence of Apaf-1. On the other hand, Stepczynska et al. (34) suggested that a mitochondria-independent pathway was responsible for the staurosporine-induced apoptosis, because a dominant-negative Caspase-9 cannot inhibit it. Manns et al. (35) recently claimed that a non-canonical staurosporine-induced apoptosis pathway requires Caspase-9 but not Apaf-1. In this report, we showed that staurosporine could activate caspase-dependent apoptosis via
two different intrinsic pathways. The first, probably present ubiquitously, is the canonical mitochondria pathway that requires Bax/Bak, Apaf-1 and Caspase-9. The second pathway does not require the components for the mitochondrial pathway, and seems to work in a cell-type-specific manner. That is, staurosporine strongly activates the second pathway in the lymphocytes, but not embryonic fibroblasts, which apparently do not express the necessary components. This cell specificity of the non-canonical intrinsic apoptotic pathway may explain the previous controversial results on staurosporine-induced cell death, which were obtained with different cell lines and tissues (11, 34, 35).

Fetal thymocytes that lacked the canonical mitochondrial apoptotic pathway, and the cell lines derived from them, efficiently underwent caspase-dependent apoptosis by staurosporine treatment, which agrees with the observation that many apoptotic cells are present in the Apaf-1-null E14.5 fetal thymus (14). These apoptotic cells are observed in the E14.5 but not the E17.5 fetal thymus of Apaf-1-null embryos. In the E14.5 fetal thymus, most of the thymocytes are at the CD4−CD8− stage, whereas in the E17.5 or neonate thymus, most of the thymocytes are at the CD4+CD8+, CD4+CD8−, or CD4−CD8+ stage. Three major selection processes occur during thymocyte development. In one of them, β-selection, immature thymocytes that productively rearrange the gene segments of the TCRβ locus undergo proliferative expansion and mature to the CD4+CD8+ stage, while those failing to do so die by apoptosis (36). It is tempting to speculate that the non-canonical Apaf-1- and Caspase-1/8-independent apoptotic pathway is involved in the apoptosis accompanying β-selection. In any case,
staurosporine and its derivatives, in particular, UCN-01, are under clinical trial as anti-cancer drugs (37, 38). Understanding how these kinase inhibitors cause apoptotic cell death will be essential for developing efficient treatment paradigms.
Materials and Methods

Mice. C57BL/6 mice were purchased from Nippon SLC (Hamamatsu, Japan). The $Apaf-1^{-/-}$ (11) and $Caspase-9^{-/-}$ (12) mice were maintained on a C57BL/6 background, and the $Bax^{-/-}Bak^{-/-}$ (20, 39) and $Tie2Cre^+Bax^{flo}Bak^{-/-}$ (40, 41) mice were on a mixed genetic background between C57BL/6 and 129/Sv. The mice were housed in a specific pathogen-free facility at the Kyoto University, Graduate School of Medicine, and all animal experiments were carried out in accordance with protocols approved by the Animal Care and Use Committee of the Kyoto University Graduate School of Medicine. To determine the genotype of the $Apaf-1$, $Caspase-9$, $Bax$, $Bak$, and $Tie2Cre$ alleles, DNA from embryonic tissues or adult tail-snip tissue was analyzed using PCR. For $Apaf-1$, wild-type- (5’-CTCAAACACCTCCTCCACAA-3’) and mutant-specific (5’-GGGCCAGCTCATTCCTC-3’) sense primers were used with a common antisense primer (5’-GTCATCTGGAAGGGCAGCGA-3’). For $Caspase-9$, 5’-AGGCCAGCCACCTCCACTCCCTC-3’ and 5’-CAGAGATGTGATAGGAAGGCGACTCC-3’ for wild-type, and 5’-CGTGCTACTTCCATTTTGTCACGTC-3’ and 5’-ACACCCTTGCAAGTCAGAGGTATG-3’ for the mutant were used. For $Bax$, wild-type- (5’-GAGCTGATCAGAACCATCATG-3’) and mutant-specific (5’-CCGCTTCCATTGTAGGTCTGAAG-3’) sense primers and a common antisense primer (5’-GTTGACCAGAGTGGCAGTAGG-3’) were used. For the floxed allele of the $Bax$ gene, wild-type- (5’-CTGGGGCGCGGATCCATTCCCACCG-3’) and mutant-specific (5’-TACGAAGTTATTAGGTCTGAAGAGG-3’) sense primers were used with a common antisense primer.
(5’-CCCTAGTAGTGACAAAGTAGCATGGAAG-3’). For Bak, wild-type-
(5’-GGTGTCCACACTAGAGAACTACTC-3’) and mutant-specific
(5’-CTATCAGGACATAGCGTTGG-3’) sense primers were used with a common
antisense primer (5’-GAGCCATGAAGATGTTTAGC-3’). For the Tie2Cre allele, a
sense primer in the Tie2 promoter region
(5’-CCCTGTGCTCAGACAGAAATGAGA-3’) was used with an antisense primer in
the Cre coding region (5’-CGCATAACCAGTGAAACAGCATTGC-3’).

**Cells, antibodies, and reagents.** Mouse embryonic fibroblasts (MEFs) were prepared
from E14.5 mouse embryos as previously described (42), and cultured in DMEM
containing 10% FCS (Gibco, Grand Island, NY). Plat-E cells (43) were cultured in
DMEM containing 10% FCS, 1 µg/ml puromycin (Clontech, Palo Alto, CA), and 10
µg/ml blasticidin S (Invitrogen, Carlsbad, CA).

Rat anti-mouse CD16/CD32 monoclonal antibody (mAb) (2.4G2) (Mouse BD Fc
Block), FITC-conjugated rat anti-mouse Thy1.2 mAb (53-2.1), PE-conjugated rat
anti-mouse CD25 mAb (7D4), Cy-Chrome-conjugated rat anti-mouse CD44 mAb
(IM7), PE-conjugated hamster anti-mouse Fas mAb (Jo2), and mouse anti-PARP mAb
(C2-10) were purchased from BD PharMingen (San Diego, CA). Rabbit monoclonal
antibodies against Caspase-3 (8G10), and GAPDH (14C10), rabbit polyclonal
antibodies against cleaved caspase 6, cleaved caspase 7, and mouse cleaved caspase 8
were from Cell Signaling (Danvers, MA). Rabbit anti-caspase 2 was from Abcam
(Cambridge, MA), and mouse anti-caspase 9 mAb (5B4) was purchased from Medical
Biological Laboratories (Nagoya, Japan). Mouse anti-α-tubulin mAb (Ab-1) was from Calbiochem (San Diego, CA), rabbit anti-Bax (N-20) Ab and anti-Bcl-2 (C 21) Ab were Santa Cruz Biotechnology (Santa Cruz, CA), rabbit anti-Bak (NT) Ab was from Millipore (Temecula, CA), and HRP-conjugated goat anti-rabbit and anti-mouse Ig Abs were from Dako (Copenhagen, Denmark). FITC-conjugated mouse anti-cytochrome c mAb (6H2.B4) was purchased from BioLegend (San Diego, CA).

Leucine-zipper-tagged human FasL was prepared as previously described (44). Cytochrome c from bovine heart, tunicamycin, cycloheximide, etoposide, sodium orthovanadate, K252a, UCN-01, SB239063, and LY294002 were purchased from Sigma-Aldrich (St Louis, MO). Actinomycin D, 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride (AEBSF), and okadaic acid were from Wako Pure Chemical (Osaka, Japan). The Caspase inhibitor, Q-VD-OPh was from R & D Systems (Minneapolis, MN). GF109203X, Ro31-8220, Ro31-6045, Ro31-6233, K252c, KT5823, and H-7 were from Enzo Life Sciences (Farmingdale, NY), H-9 was from Santa Cruz, U0126 was from Promega (Madison, WI), Gö 6976 was from LC Laboratories (Woburn, MA), KT5720 and SP600125 were from Calbiochem, and H89 was obtained from Cayman Chemical (Ann Arbor, MI).

**Plasmids.** The pCX4pur, pCX4bsr, pCX4hyg, pCX4pur/H-rasV12, and pCX4bsr/c-myc retroviral vectors (45) were provided by Dr. Tsuyoshi Akagi (KAN Research Institute, Kobe, Japan). The pCX4 vector was constructed by removing the drug selection marker. The coding sequence of mouse Fas (46) was inserted into pCX4bsr
(pCX4bsr/mFas), while the coding sequence of CrmA (47, 48) was inserted into pCX4pur (pCX4pur/crmA). The human BCL-2-expression plasmid, pEF-BOS/Bcl-2 was as previously described {Itoh, 1993 #665}.

**Production of retroviruses.** To produce retrovirus, Plat-E cultured in DMEM containing 10% FCS was transfected with expression vector using FuGENE 6 (Roche Applied Science, Basel, Switzerland). After culturing at 37°C for 48 h, the supernatant was collected, passed through a 0.45-µm filter unit (Millipore, Billerica, MA), and centrifuged at 6,000 x g for 16 h at 4°C (49). After centrifugation, the pellet was re-suspended in a 1/10 original volume of the culture medium and stored at -80°C.

**Establishment of immortalized fetal thymocytes.** Cells from the fetal thymus were immortalized by infection with retroviruses carrying H-ras<sup>V12</sup> and c-myc. That is, fetal thymocytes were cultured in the presence of IL-7 (50), then infected with retrovirus using a RetroNectin kit (Takara Bio, Shiga, Japan) coupled with centrifugation, as recommended by the supplier. In brief, the wells of a 96-well plate (flat-bottom, BD Falcon) were coated with 6 µg of RetroNectin at 4°C overnight, and then incubated at room temperature for 30 min in PBS containing 2% BSA. The retroviruses were added to the wells, and the plate was centrifuged at 2,000 x g for 2 h at room temperature, and washed with PBS. Primary E14.5 mouse fetal thymocytes were suspended in culture medium [DMEM containing 10% FCS, 1 x NEAA (non-essential amino acids), 50 µM 2-mercaptoethanol, 10 mM HEPES-NaOH (pH 7.4)] supplemented with 5 ng/ml
mouse IL-7 (PeproTech, Rocky Hill, NJ) and added to the wells. The cells were attached to the wells by centrifuging at 400 x g for 5 min, and the plate was incubated for 3 days at 37°C. E14.5 Apaf-1+/+ and Apaf-1−/− fetal thymocytes were infected with retroviruses from pCX4pur/H-rasV12 and pCX4bsr/c-myc. Other thymocytes were infected with retroviruses from pCX4/H-rasV12 and pCX4/c-myc. A single clone of each genotype was obtained by limiting dilution.

**Transfection of IFET.** To express mouse Fas and CrmA, 1 x 10⁵ IFETs in 12-well flat bottom plates were suspended in the culture medium containing retrovirus and 10 μg/ml polybrene (Sigma-Aldrich), centrifuged at 1,000 x g for 1 h at room temperature (51, 52), and cultured at 37°C for 24 h. Puromycin or blasticidin was added to the culture at a final concentration of 5 μg/ml or 50 μg/ml, and the cells were further incubated for 7 or 10 days, respectively. The BCL-2 expression plasmid, pEF-BOS/Bcl-2, was introduced into IFETs by electroporation together with hygromycin-resistant gene pCX4hyg, and the stable transformants were selected by culturing in the presence of 4 mg/ml hygromycin B (Wako Pure Chemicals).

**FACS analysis.** To examine the expression of surface antigens, 1 x 10⁵ IFETs in 96-well round-bottom plates were centrifuged at 300 x g for 3 min at 4°C, washed with FACS staining buffer (2% FCS and 0.02% NaN₃ in PBS), pretreated with Fc block, stained with fluorescent dye-conjugated antibodies, and analyzed by FACSCalibur (BD).
To detect phosphatidylserine exposed on apoptotic cells, 6.25 x 10^4 cells were incubated at room temperature for 15 min with 500-fold diluted Cy5-conjugated Annexin V (BioVision, Mountain View, CA) in 0.5 ml of Annexin V staining buffer [10 mM HEPES-NaOH (pH 7.4), 140 mM NaCl, and 2.5 mM CaCl_2]. Propidium iodide (PI) was added to a final concentration of 2.5 µg/ml, and the samples were incubated at room temperature for 5 min, and analyzed by FACSCalibur (53).

**Cell-free assay for Caspase-3 activation.** The cytochrome c-induced activation of Caspase-3 was assayed essentially as described (54). In brief, IFETs were harvested by centrifugation at 400 x g for 5 min at 4°C, washed with extraction buffer [50 mM PIPES-KOH (pH 7.0), 20 mM KCl, 5 mM EGTA, 1 mM DTT, and 10 mM AEBSF], and suspended in 0.8 volumes of the extraction buffer. After incubation on ice for 20-30 min, the cells were disrupted in a Dounce homogenizer (Wheaton, Millville, NJ) with 100 strokes of a tight pestle. The cell lysates were subjected to centrifugation at 10,000 x g for 10 min at 4°C, and the supernatant was further centrifuged at 100,000 x g for 1 h at 4°C to obtain the S-100 fraction. Protein (100 µg) of the S-100 fraction was incubated at 37°C for 30 min with 200 µM dATP and 4 µM cytochrome c in 25 µl of the extraction buffer. The reaction was stopped by placing the reaction mixture on ice, and the sample was mixed with an equal volume of 2 x SDS sample buffer [125 mM Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 0.02% BPB, and 10% 2-mercaptoethanol] for Western blotting.
**Assay for apoptosis.** To induce apoptosis, IFETs, primary thymocytes and splenocytes, bone-marrow cells treated with erythrocyte lysis buffer, and MEF at passage 3 were suspended at 1 x 10^6, 1 x 10^7, 5 x 10^6, and 5 x 10^4 cells/ml in the culture medium, respectively, and incubated at 37°C with 10 μM staurosporine, 50 μM etoposide. To induce apoptosis by γ-rays, the cells were irradiated with 5 Gy using a 137Cs gamma-irradiator (dose rate of 0.744 Gy/min in a Gammacell 40 Exactor, Nordion International, Kanata, Ontario, Canada), and incubated at 37°C. Viable cells were counted by the trypan blue exclusion assay.

**Western blot analysis.** Cells were harvested by centrifugation at 1,100 x g for 5 min at 4°C, washed with PBS, suspended at 1.0-10 x 10^7 cells /ml in RIPA buffer [50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP40, 0.1% SDS, and 0.5% sodium deoxycholate] containing a protease inhibitor cocktail (cOmplete, Mini, Roche), and incubated on ice for 15 min. Samples were centrifuged at 13,000 x g for 15 min at 4°C. The protein concentration of the supernatant was adjusted to 0.5 mg/ml with RIPA buffer, and the sample was mixed with an equal volume of 2 x SDS sample buffer. After incubating at 98°C for 5 min, the proteins were separated by 10-20% gradient SDS–PAGE if not specified, and transferred to PVDF membranes (pore size: 0.22 μm or 0.45 μm, Millipore). After incubation at room temperature for 1 h with blocking buffer [TBST (Tris-buffered saline containing 0.05% Tween 20) supplemented with 5% non-fat dry milk], the membranes were stained with primary antibodies in blocking buffer or solution 1 (Can Get Signal Immunoreaction Enhancer Solution; Toyobo,
Osaka, Japan) at room temperature for 1 h or at 4°C overnight. After being washed with TBST, the membranes were incubated at room temperature for 1 h with HRP-conjugated secondary antibodies in blocking buffer or solution 2. The proteins recognized by the antibody were then visualized by a chemiluminescence reaction (Immobilon Western, Millipore) and detected by the LAS-4000 system (Fujifilm Co., Tokyo, Japan).

**Clonogenic assay.** After washing with PBS containing 0.1% BSA, IFETs were re-suspended at a final concentration of 1 x 10^6 cells/ml in pre-warmed PBS containing 0.1% BSA and 10 μM CFSE (Molecular Probes, Eugene, OR), and incubated at 37°C for 10 min. The staining reaction was stopped by addition of 5 volumes of ice-cold IFET culture medium, and incubated on ice for 5 min. After washing twice with ice-cold culture media, the CFSE stained-cells were pretreated with 50 μM Q-VD-OPh for 1 h in the culture media, and further treated at 37°C for 30 min with 10 μM staurosporine in the presence of 50 μM Q-VD-OPh. The cells were then washed with ice-cold culture media, and cultured at 37°C for 2 days in the culture medium containing 50 μM Q-VD-OPh. Then, the cells were stained at room temperature for 15 min with 1:1000 diluted Cy5-Annexin V in Annexin V staining buffer, and were analyzed by FACSCalibur.

**Cytochrome c release assay.** The apoptotic cytochrome c-release was assayed as described previously (55). In brief, 1 x 10^5 IFETs were treated at 37°C for 2 h with 10
µM staurosporine, and treated for 5 min on ice with 50 µg/ml digitonin in 100 µl of PBS containing 100 mM KCl until >95% cells were permeabilized as assessed by trypan blue exclusion. IFETs were washed with FACS staining buffer, fixed for 20 min at room temperature with 4% paraformaldehyde in PBS, washed three times, and incubated at room temperature for 1 h in blocking buffer (PBS containing 3% BSA and 0.05% saponin). The cells were then incubated for 1 h at room temperature in 1:200 diluted FITC-conjugated anti-cytochrome c mAb, washed, and analyzed by FACSCalibur.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgments. We thank Dr. Tsuyoshi Akagi (KAN Research Institute, Kobe, Japan) for the pCX4 series vectors, Dr. Shin Yonehara (Graduate School of Biostudies, Kyoto University) for the Caspase-9−/− mice in a C57/B6 background, and Dr. Osamu Takeuchi (Virus Institute, Kyoto University) for the Bax−/−Bak−/− and Baxfl/flBak−/− mice, and the Tie2-Cre transgenic mice. We are grateful to Drs. Masamichi Ishiai and Minoru Tanaka (Radiation Biology Center, Kyoto University) for help with the γ-irradiation. We thank Ms. Makiko Fujii for secretarial assistance. This work was supported in part by Grants-in-Aid for Specially Promoted Research from the Ministry of Education, Science, Sports, and Culture in Japan. T.I. is a Research Fellow...
of the Japan Society of the Promotion of Science.
Reference


42. Okabe Y, Kawane K, Akira S, Taniguchi T, Nagata S. Toll-like


47. Pickup DJ, Ink BS, Hu W, Ray CA, Joklik WK. Hemorrhage in lesions caused by cowpox virus is induced by a viral protein that is related to plasma protein inhibitors of serine proteases. *Proc Natl Acad Sci USA* 1986; **83**: 7698-7702.


Legends to Figures

Figure 1. Staurosporine-induced Apaf-1-independent apoptosis. (A) Apaf-1-independent cell death induced by staurosporine but not etoposide. *Apaf-1*<sup>+/+</sup> (+/+) and *Apaf-1*<sup>-/-</sup> (-/-) IFETs were cultured with 10 µM staurosporine (STS) or 50 µM etoposide (Eto). At the indicated time, living cells were counted by trypan blue exclusion assay, and expressed as a percentage of the initial cell number. The experiments were carried out independently for three times, and the average number was plotted with S.D. (bars). (B) Caspase-dependent Apaf-1-independent cell death induced by staurosporine. *Apaf-1*<sup>+/+</sup> (+/+) and *Apaf-1*<sup>-/-</sup> (-/-) IFETs were pre-treated with 50 µM Q-VD-OPh (Q) for 1 h, and cultured with or without 10 µM staurosporine (STS) and 50 µM Q-VD-OPh for the indicated times. Living cells were counted by trypan blue exclusion assay, and expressed as a percentage of the initial cell number. Experiments were performed independently for three times, and the average values were plotted with S.D. (bars). (C) *Apaf-1*-independent caspase activation by staurosporine but not etoposide. *Apaf-1*<sup>+/+</sup> (WT) and *Apaf-1*<sup>-/-</sup> IFETs were treated with 10 µM staurosporine (STS) for 2 h or 50 µM etoposide (Eto) for 6 h. Cell lysates were analyzed by Western blot with anti-Caspase-3, anti-cleaved Caspase 2, anti-cleaved Caspase 6, anti-cleaved Caspase 8, anti-Caspase 9, anti-PARP or anti-α-tubulin Abs. Except for the Western blot for PARP, where the cell lysates were separated by 7.5% SDS-PAGE, the cell lysates were separated by 5-20% SDS-PAGE. Arrows indicate the pro- and activated form of Caspase, and non-cleaved (113 kDa) and cleaved PARP (85 kDa). (D) *Apaf-1*-independent PS exposure. *Apaf-1*<sup>+/+</sup> (WT) and *Apaf-1*<sup>-/-</sup> IFETs
were treated with 10 µM staurosporine (STS) for 2 h or with 50 µM etoposide (Eto) for 8 h, stained with Cy5-conjugated Annexin V and PI, and analyzed by FACS. Cells with no treatment (-) were analyzed similarly, and FACS profiles are shown at left. Numbers indicate the percentage of the cells in each quadrant.

**Figure 2.** No requirement for the mitochondrial or death receptor apoptosis pathway for the staurosporine-induced Caspase activation. (A) Requirement of the mitochondrial pathway for etoposide-induced but not staurosporine-induced Caspase-3 activation. Wild-type (WT), *Apaf-1*<sup>-/-</sup>, *Caspase-9*<sup>-/-</sup>, and *Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> IFETs were treated with 10 µM staurosporine (STS) for 2 h or with 50 µM etoposide (Eto) for 6 h. The cell lysates were analyzed by Western blotting with anti-Caspase-3 or anti-tubulin Abs. Arrows indicate pro- and cleaved Caspase-3. (B) No requirement of the cytochrome c-release from mitochondria in the staurosporine-induced Caspase-3 activation. The wild-type, *Apaf-1*<sup>-/-</sup>, and *Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> IFETs were treated with 10 µM staurosporine, permeabilized with digitonin, fixed with parafomaldehyde, and stained with anti-cytochrome c (straight line), followed by FACS analysis. The cytochrome c-staining profile before the staurosporine-treatment is shown by dotted line. (C) No requirement for the death receptor pathway in the staurosporine-induced Caspase-3 activation in IFETs. *Fas-Casp9*<sup>-/-</sup> IFETs transformed with empty vector or CrmA were treated with 6.6 U/ml Fas ligand (FasL)(left) or with 10 µM staurosporine (STS)(right) for 2 h. The cell lysates were analyzed by Western blotting with anti-Caspase-3 and anti-α-tubulin Abs. Arrows indicate pro- and cleaved Caspase-3.
Figure 3. Requirement of the mitochondrial pathway for the tunicamycin-, actinomycin D-, cycloheximide-, and γ-ray-induced caspase activation in IFETs. Wild-type, Apaf-1−/− (A–C), Caspase 9−/− (E), or Bax−/−Bak−/− (D and E) IFETs were treated with 2.5 µg/ml tunicamycin (Tun) for 6 h (A and E), 3 µg/ml actinomycin D (actD), 10 µg/ml cycloheximide (CHX) for 2 h (B and E), or 5 Gy γ-irradiation (C and D), and incubated at 37°C for 4 h. The cell lysates were analyzed by Western blotting with anti-Caspase-3 or anti-α-tubulin Abs. Arrows indicate pro- and cleaved Caspase-3.

Figure 4. Involvement of serine/threonine kinase in the staurosporine-induced Apaf-1-independent apoptosis. (A) Effect of phosphatase inhibitors on the staurosporine-induced Apaf-1-independent Caspase-3 activation. Apaf-1−/− IFETs were treated with 10 µM staurosporine (STS) and 1 µM okadaic acid (OA) or 1 mM orthovanadate (VO4) for 2 h. The cell lysates were analyzed by Western blotting with anti-Caspase-3 or anti-α-tubulin Abs. Arrows indicate pro- and cleaved Caspase-3. (B) Effect of okadaic acid on the staurosporine-induced Apaf-1-independent cell death. Apaf-1−/− IFETs were cultured without or with 10 µM staurosporine (STS) or 1 µM okadaic acid (OA), or both. At the indicated times, living cells were counted by the trypan blue exclusion assay, and are expressed as a percentage of the initial cell number. Experiments were carried out independently for three times, and the average values are plotted with S.D. (bars). (C) Apaf-1-independent Caspase-3 activation by kinase
inhibitors. *Apaf-1*⁻/⁻ IFETs were treated at 37°C for 2 h with 10 μM staurosporine (STS) or its derivatives [25 μM UCN-01, 50 μM GF109203X, 50 μM Ro31-6045, 50 μM Ro31-6233, 25 μM Ro31-8220, 2.5 μM K252a, 25 μM K252c, 50 μM Gö 6976, 50 μM KT5720, or 50 μM KT5823] or H-series kinase inhibitors [1 mM H7, H8, or H-9, or 50 μM H89]. The cell lysates were analyzed by Western blotting with anti-Caspase-3 or anti-α-tubulin Abs.

**Figure 5.** Tissue-specificity of the non-canonical apoptotic pathway. Wild-type and *Apaf-1*⁻/⁻ embryonic fibroblasts (MEF) at passage 3 (A), and thymocytes (B and C), bone marrow cells (D) and splenocytes (E) from *Bax*⁻/⁻*Bak*⁻/⁻ or *Tie2Cre*⁺*Bax*⁻/⁻*Bak*⁻/⁻ mice were treated with 10 μM staurosporine (STS) for 4 h, or 50 μM etoposide (Eto) for 7 h. In (A), (C), (D) and (E), the cell lysates were analyzed by Western blotting with anti-Caspase-3, anti-Bax, anti-tubulin, or anti-GAPDH Ab. Arrows indicate pro- and cleaved Caspase-3. In (B), at the indicated times, living cells were counted by the trypan blue exclusion assay, and are expressed as a percentage of the initial cell number. Experiments were carried out independently for three times, and the average values are plotted with S.D. (bars).
Imao et al. Fig. 4
Supplementary Figure 1. Establishment of Apaf-1−/−, Caspase 9−/−, and Bax−/−Bak−/− IFETs. IFETs established from Apaf-1+/+ and Apaf-1−/− (A), Caspase-9−/− (C), and Bax−/−Bak−/− fetal thymocytes (D) were genotyped by PCR using the primers indicated in the upper panel in each figure. DNA from Apaf-1+/+, Apaf-1+/−, and Apaf-1−/− (A), Caspase-9+/+, Caspase-9+/−, and Caspase-9−/− (C), and Bax−/−Bak−/−, Bax+/−Bak+/−, and Bax+/+Bak+/+ (D) mice was similarly analyzed and is shown as a control. Above the PCR data in (A), (C), and (D), the chromosomal gene structure of wild-type and null alleles was schematically drawn, in which exons and neomycin-resistant gene (Neo) are indicated by black and white boxes, respectively, and major recognition sites for restriction enzymes are shown. In (B), Proteins of the S-100 fraction were incubated at 37°C for 30 min with or without dATP and cytochrome c, separated by 10-20% gradient SDS-PAGE, and analyzed by Western blotting with an anti-Caspase-3 or anti-α-tubulin antibody. Arrows indicate pro- and cleaved Caspase-3.
Supplementary Figure 2. Phenotype of IFETs. Apaf-1<sup>+/+</sup> and Apaf-1<sup>−/−</sup> IFETs were stained with FITC-conjugated anti-Thy1.2, PE-conjugated anti-CD25, or Cy-Chrome-conjugated anti-CD44 antibodies, and analyzed by flow cytometry (filled area). Profiles of non-stained cells are shown in open area.
Supplementary Figure 3. No effect of caspase inhibitor on the clonogenicity of IFETs treated with staurosporine. The CFSE-labelled Bax⁻/⁻ Bak⁻/⁻ IFETs were cultured in the absence or presence of Q-VD-OPh, and treated with 10 µM staurosporine (STS) for 30 min. The cells were further cultured for 2 days in medium with or without Q-VD-OPh, stained with Annexin V-Cy5, and analyzed by FACSCalibur for CFSE and Annexin V.
**Supplementary Figure 4.** Time- and dose-dependent Caspase-3-activation by staurosporine. The wild-type and *Apaf-1*⁻/⁻ IFETs were treated with 10, 1.0, and 0.1 µM staurosporine (STS) for the indicated times, and the cell lysates were analyzed by Western blotting with anti-Caspase-3 and anti-α-tubulin Abs. Arrows indicate pro- and cleaved Caspase-3.
**Supplementary Figure 5.** No effect of Bcl-2 on the Apaf-1-independent staurosporine-induced Caspase 3-activation. *Apaf-1*^-/-^ IFETs were transformed with human BCL-2, and treated with 10 µM staurosporine (STS) for 2 h. The cell lysates were analyzed by Western blotting with anti-Bcl-2, anti-Caspase-3, and anti-α-tubulin Abs. Arrows indicate human and mouse Bcl-2 (A). Pro- and cleaved Caspase-3 are indicated by arrows (B).
**Supplementary Figure 6.** Transformation of Caspase 9−/− IFETs with Fas. Caspase-9−/− IFETs were transformed with mouse Fas, then crmA or empty vector was further introduced. The cells were stained with PE-conjugated anti-mouse Fas mAb (shaded area), and analyzed by FACS. The FACS profile of non-stained cells is shown by an open area.
Supplementary Figure 7. No Caspase-3 activation in Apaf-1\(^{-/-}\) IFETs by inhibitors of MAPK and PI3K pathways. The Apaf-1\(^{-/-}\) IFET cells were treated with 10 µM staurosporine (STS), 20 µM U0126 (U), 20 µM SP600125 (SP), 20 µM SB 239063 (SB), 50 µM LY294002 (LY), 20 µM U0126 and 50 µM LY294002 (U/LY), or 20 µM U0126, 20 µM SP600125, 20 µM SB 239063, and 50 µM LY294002 (U/SP/SB/LY) for 2 h. The cell lysates were separated by 10-20% gradient SDS-PAGE, and analyzed by Western blot with anti-Caspase-3 (Top panel) and anti-\(\alpha\)-tubulin (bottom panel) antibodies. Arrows indicate pro- and activated forms of Caspase-3.
**Supplementary Figure 8.** Characterization of Tie2Cre<sup>+</sup>Bax<sup>0/0</sup>Bak<sup>−/−</sup> mice. (A) Genotyping. Chromosomal DNA from Bax<sup>0/0</sup>Bak<sup>−/−</sup>, Tie2Cre<sup>+</sup>Bax<sup>0/0</sup>Bak<sup>−/−</sup>, and the wild-type C57BL/6 mice were analyzed by PCR for the Tie2-Cre, the wild-type and floxed Bax, the wild-type and mutant Bak alleles. The primes used for PCR are indicated in right. (B) No expression of Bak in Bak-deficient mice. The cell lysates from the thymocytes and splenocytes of Bax<sup>0/0</sup>Bak<sup>−/−</sup>, Tie2Cre<sup>+</sup>Bax<sup>0/0</sup>Bak<sup>−/−</sup>, and the wild-type C57BL/6 mice were analyzed by Western blotting with anti-Bak and anti-tublin Abs.